Literature DB >> 11035385

Pathophysiology of erectile dysfunction: the contributions of trabecular structure to function and the role of functional antagonism.

R B Moreland1.   

Abstract

Erectile dysfunction (ED) is estimated to impact more than 150 million men this year worldwide. An understanding of the pathophysiology of ED both furthers the basic scientific knowledge of disease processes and provides a rational design of pharmacotherapy. At present, there are two major views regarding the pathophysiology of ED. In the first hypothesis, the oxygen tension-dependent changes in the penis during erection are proposed to impact corpus cavernosum structure by inducing various cytokines, vasoactive factors and growth factors at the two different oxygen tensions (flaccidity and erection) which, in turn, alter smooth muscle metabolism and connective tissue synthesis. Decreases in the corpus cavernosum smooth muscle/connective tissue ratio have been correlated with an increased likelihood of diffuse venous leak and a failure of the veno-occlusive mechanism in prospective patient studies. Evidence for such a hypothesis incorporates nocturnal penile tumescence and circadian changes in oxygenation as important in maintaining erectile health. The alternate hypothesis proposes that ED is the result of a metabolic imbalance between relaxatory and contractile processes within the trabecular smooth muscle such that contractile processes predominate. Based on this hypothesis, therapy can be accomplished via drugs which shift this balance towards vasodilatation, or by gene therapy approaches to supplement the deficient components favoring smooth muscle relaxation. Both of these hypotheses predict a management strategy for ED that impacts pharmacotherapeutics. In this review of the pathophysiology of ED, each hypothesis will be examined and a synthesis devised incorporating both views. The future of research in this area as well as pharmacotherapy in ED in terms of pathophysiology is discussed including the merits and drawbacks of prophylaxis and prevention of ED. International Journal of Impotence Research (2000) 12, Suppl 4, S39-S46.

Entities:  

Mesh:

Year:  2000        PMID: 11035385     DOI: 10.1038/sj.ijir.3900576

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  14 in total

Review 1.  Cavernous smooth muscles: innovative potential therapies are promising for an unrevealed clinical diagnosis.

Authors:  Ahmed Mohamed Hassanin; Ahmed Zain Abdel-Hamid
Journal:  Int Urol Nephrol       Date:  2019-10-15       Impact factor: 2.370

2.  Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction.

Authors:  Maarten Albersen; Guiting Lin; Thomas M Fandel; Haiyang Zhang; Xuefeng Qiu; Ching-Shwun Lin; Tom F Lue
Journal:  Urology       Date:  2011-05-31       Impact factor: 2.649

3.  Erectile tissue molecular alterations with aging: differential activation of the p42/44 MAP Kinase pathway.

Authors:  Angela Castela; Raquel Soares; Fátima Rocha; Pedro Vendeira; Ronald Virag; Carla Costa
Journal:  Age (Dordr)       Date:  2010-07-14

4.  Androgen depletion in humans leads to cavernous tissue reorganization and upregulation of Sirt1-eNOS axis.

Authors:  Inês Tomada; Nuno Tomada; Henrique Almeida; Delminda Neves
Journal:  Age (Dordr)       Date:  2011-11-04

Review 5.  [Pathophysiology and rehabilitation of erectile dysfunction after nerve-sparing radical prostatectomy].

Authors:  C van der Horst; F J Martinez-Portillo; K P Jünemann
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

6.  The correlation between high sensitivity C-reactive protein and erectile dysfunction patients with hypertension treated with vardenafil.

Authors:  S Azab; H Aoud; N Nabil
Journal:  Int J Impot Res       Date:  2016-12-01       Impact factor: 2.896

Review 7.  Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction.

Authors:  Biljana Musicki; Anthony J Bella; Trinity J Bivalacqua; Kelvin P Davies; Michael E DiSanto; Nestor F Gonzalez-Cadavid; Johanna L Hannan; Noel N Kim; Carol A Podlasek; Christopher J Wingard; Arthur L Burnett
Journal:  J Sex Med       Date:  2015-12-08       Impact factor: 3.802

8.  Testosterone, endothelial health, and erectile function.

Authors:  Angela Castela; Pedro Vendeira; Carla Costa
Journal:  ISRN Endocrinol       Date:  2011-09-06

9.  Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment.

Authors:  Valter Javaroni; Mario Fritsch Neves
Journal:  Int J Hypertens       Date:  2012-05-09       Impact factor: 2.420

Review 10.  Intracavernous pharmacotherapy for erectile dysfunction.

Authors:  Anthony J Bella; Gerald B Brock
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.